Management of Wolff-Parkinson-White Syndrome

Medication Recommendations

• The European Society of Cardiology recommends avoiding medications classified as Class III: Harm recommendation with Level of Evidence B, such as AV nodal blocking agents (e.g., beta-blockers, calcium channel blockers, and digoxin) in patients with Wolff-Parkinson-White syndrome and atrial fibrillation, as they can accelerate conduction through the accessory pathway and precipitate ventricular fibrillation 1, 2, 3
• Amiodarone may be considered in select cases for long-term management until definitive treatment, according to the European Society of Cardiology, while adenosine, non-dihydropyridine calcium channel blockers (verapamil, diltiazem), digoxin, and beta-blockers are contraindicated in patients with Wolff-Parkinson-White syndrome, classified as a Class III: Harm recommendation with Level of Evidence B by the American College of Cardiology/American Heart Association/European Society of Cardiology 1, 2, 3
• Immediate direct-current cardioversion is the first-line treatment for patients with Wolff-Parkinson-White syndrome, classified as a Class I recommendation, and for pre-excited atrial fibrillation, IV procainamide or ibutilide are the preferred medications, also classified as a Class I recommendation 2, 4, 5, 6, 1
• Alternative antiarrhythmic options, such as IV quinidine, IV disopyramide, IV ibutilide, and IV amiodarone (with caution), may be considered (Class IIb recommendation, Level of Evidence: B) 4, 6, 1

Risk Stratification and Indications for Catheter Ablation

• The following risk factors for sudden cardiac death are indications for catheter ablation:

5, 7, 8

• Catheter ablation of the accessory pathway is indicated for all symptomatic patients with Wolff-Parkinson-White syndrome and atrial fibrillation, especially those with a history of syncope, short accessory pathway refractory period (<250 ms), or multiple accessory pathways (Class I recommendation, Level of Evidence: B) 4, 5, 6, 1

Management in Special Populations

• In pregnant patients with WPW, direct-current cardioversion is recommended for hemodynamically unstable patients by the European Heart Society, and a multidisciplinary approach involving cardiology, obstetrics, and anesthesiology is recommended for pregnant patients with WPW syndrome 1, 9
• Vaginal delivery is preferred in hemodynamically stable patients, but consider early cesarean delivery if ventricular function deteriorates or arrhythmias become difficult to control, as recommended by the European Heart Journal 9
• Beta-blockers are generally compatible with breastfeeding (metoprolol preferred), but women taking D-penicillamine should not breastfeed, as recommended by the Hepatology journal 10

Follow-up and Monitoring

• Regular cardiac monitoring and risk reassessment are recommended for patients with WPW syndrome, with ECG evaluation at 3 months and annually during the first years, and patient education about symptoms requiring immediate medical attention is essential 11
• Continuous cardiac monitoring during and after conversion is essential to assess for recurrence of arrhythmia 11
• The risk of sudden cardiac death in WPW ranges from 0.15% to 0.6% per year, with the highest risk in the first two decades of life, and risk stratification is essential to assess for risk factors for sudden cardiac death 11, 12